Chondroitin sulfate proteoglycan cspg

Fluidic isolation between the center soma compartment and the axon compartments was achieved by the fluidic level difference. During the localized biomolecular treatment to the isolated axons, the soma compartment is set to have slightly higher fluidic level compared to the axon compartments, thereby preventing biomolecules added into the axon compartments from diffusing or flowing into the soma compartment. The concept has been well established by us as well as others [15 (link),32 (link),33 (link),34 (link),35 (link),36 (link),37 (link)]. In addition, in order to demonstrate that the device is capable of performing six different biomolecular treatments in a single device in parallel, 5 µg/mL of chondroitin sulfate proteoglycan (CSPG) (Millipore, Billerica, MA, USA), known to cause degeneration of axons, were added to the two reservoirs in the middle [38 (link),39 (link)].

293T/17, COS7, SH-SY5Y cells were routinely maintained in DMEM containing 10% Fetal Bovine Serum and 1% penicillin/streptomycin. The following antibodies were used: Anti-PTPRS clone 1H6 (Abnova), Anti-RPTPσ clone 17G7.2 (MediMabs), Anti-tubulin (Sigma). The following reagents were used in this study: Chondroitin Sulfate (Sigma), Heparin (Sigma), Aggrecan (Sigma) and Chondroitin Sulfate Proteoglycan (CSPG) (Millipore), D-luciferin (ThermoFisher Scientific).